EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling

Sandip Mukherjee, Molee Chakraborty, Jake Haubner, Glen Ernst, Michael DePasquale, Danielle Carpenter, James C Barrow iD, Anutosh Chakraborty

Biomolecules · 2023

DOI: 10.3390/biom13050868 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Sandip Mukherjee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Insulin Resistance, Hyperglycemia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIMH NIH HHS, Saint Louis University (SLU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity and nonalcoholic fatty liver disease (NAFLD) are global health concerns, and thus, drugs for the long-term treatment of these diseases are urgently needed. We previously discovered that the inositol pyrophosphate biosynthetic enzyme IP6K1 is a target in diet-induced obesity (DIO), insulin resistance, and NAFLD. Moreover, high-throughput screening (HTS) assays and structure−activity relationship (SAR) studies identified LI-2242 as a potent IP6K inhibitor compound. Here, we tested the efficacy of LI-2242 in DIO WT C57/BL6J mice. LI-2242 (20 mg/kg/BW daily, i.p.) reduced body weight in DIO mice by specifically reducing the accumulation of body fat. It also improved glycemic parameters and reduced hyperinsulinemia. LI-2242-treated mice displayed reduced the weight of various adipose tissue depots and an increased expression of metabolism- and mitochondrial-energy-oxidation-inducing genes in these tissues. LI-2242 also ameliorated hepatic steatosis by reducing the expression of genes that enhance lipid uptake, lipid stabilization, and lipogenesis. Furthermore, LI-2242 enhances the mitochondrial oxygen consumption rate (OCR) and insulin signaling in adipocytes and hepatocytes in vitro. In conclusion, the pharmacologic inhibition of the inositol pyrophosphate pathway by LI-2242 has therapeutic potential in obesity and NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseInsulin ResistanceHyperglycemiaMiceAnimalsDiphosphatesInsulinObesityDietLipidsInositolMice, Inbred C57BLLiverLipid Metabolism

Stichwörter der Autor:innen

IP6K1LI-2242NAFLDinsulin resistanceobesity

Substanzen

diphosphoric acidDiphosphatesInsulinLipidsInositol

Autor:innen und Institutionen

  • Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA.
  • Lieber Institute for Brain Development and Department of Pharmacology, Johns Hopkins University School of Medicine, 855 North Wolfe Street Suite 300, Baltimore, MD 21205, USA.

ORCID-Profile: James C Barrow

Förderung

  • NIDDK NIH HHS
  • NIMH NIH HHS
  • Saint Louis University (SLU)

Zitieren

APA

Mukherjee, S., Chakraborty, M., Haubner, J., Ernst, G., DePasquale, M., Carpenter, D., Barrow, J. C., & Chakraborty, A. (2023). The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling. Biomolecules. https://doi.org/10.3390/biom13050868

Vancouver

Mukherjee S, Chakraborty M, Haubner J, Ernst G, DePasquale M, Carpenter D, et al. The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling. Biomolecules. 2023. doi:10.3390/biom13050868

BibTeX
@article{Mukherjee2023,
  author = {Mukherjee, Sandip and Chakraborty, Molee and Haubner, Jake and Ernst, Glen and DePasquale, Michael and Carpenter, Danielle and Barrow, James C and Chakraborty, Anutosh},
  title = {The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13050868}
}
Kostenlos starten →